课题基金 / 基金详情

ACTG 303--INFLUENCE OF RISK STATUS PROGRESSION ON RESPONSE TO ANTIRETROVIRALS

ACTG 303--INFLUENCE OF RISK STATUS PROGRESSION ON RESPONSE TO ANTIRETROVIRALS
ACTG 303--风险状态进展对抗逆转录病毒药物反应的影响
批准号：
6279915
负责人：
DAVID IVES
金额：
$2.49万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6279915
关键词：
AIDS therapy antiAIDS agent clinical research combination chemotherapy disease /disorder proneness /risk drug screening /evaluation human subject human therapy evaluation nucleoside analog

项目摘要

项目成果

DAVID IVES的其他基金

相似基金

相关文献

中文摘要
翻译
这项后续试验对这些受试者进行了随机、双盲、
英文摘要
This follow-up trial for those subjects in a randomized, double-blind, phase 2/3 trial of monotherapy vs. combination therapy with nucleoside analogues in HIV-infected persons with CD4 cells <=200 or >=500 mm3 provides the opportunity to carefully characterize subjects who have a well-defined nucleoside analog exposure history with respect to their symptomatic state, their CD4 trajectory, and their virologic profile, and to relate this to the response to new antiretroviral interventions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ACTG 368--IDV, DMP2268, AND 1592U89 IN HIV SUBJECTS
ACTG 360: OBSERVATIONAL STUDY OF CMV & HIV VIRAL BURDEN
ACTG 362: EFFICACY OF AZITHROMYCIN PROPHYLAXIS AGAINST MAC DISEASE
ACTG 328--INTERMITTENT RHIL 2 BY IV OR SQ ADMINISTRATION ON HAART VS HAART ONLY
海外基金